MilliporeSigma and ReForm Collaborate on Excipient Commercialization
The companies have entered into a global licensing and collaboration agreement to commercialize ReForm excipients used in biotherapeutic formulations.
MilliporeSigma and ReForm Biologics, a formulation innovation company based in Woburn, MA, announced on Feb. 10, 2020 that they have entered into a global licensing and collaboration agreement to commercialize ReForm excipients used in biotherapeutic formulations.
Through the agreement, MilliporeSigma will handle the research, development, global commercialization, GMP manufacturing, and sale of the excipients, and ReForm will collect revenues from MilliporeSigma for sublicensing their technology to MilliporeSigma’s biologic formulations, according to a ReForm press release.
“MilliporeSigma is a global leader in providing pharmaceutical excipients for biologic formulation. This agreement will make ReForm Biologics’ excipients available through their GMP manufacturing and distribution network, accelerate our research and development activities, and greatly expand our presence in biological drug development,” said John M. Sorvillo PhD, CEO, ReForm, in the press release. “As more biologics are being developed to treat a broad range of diseases ranging from cancer to orphan indications, we believe there will be a growing demand for new excipients that can enhance the patient experience, improve patient outcomes, and potentially extend the patent life of a therapeutic.”
Source: ReForm
